OPTIMISMM is an international, randomized, open-label, controlled, phase 3 clinical trial (NCT01734928)….In all patients treated with PVd at first relapse, PFS and ORR were significantly improved vs in those treated with Vd (PFS: median, 20.73 vs 11.63 months; HR, 0.54 [95% CI, 0.36–0.82]; P = 0.0027...ORR: 90.1 vs 54.8%; odds ratio [OR], 7.50 [95% CI, 3.64–15.46]; P < 0.001; Supplemental Table 2).